Immunotherapy-intensified paraneoplastic dermatomyositis

To conclude, dermatomyosits can be a serious complication during treatment with immune checkpoint inhibitor, requiring drug discontinuation and systemic corticosteroids in most patients. Clinicians should be aware of this potential complication of immunotherapy and closely monitor musculoskeletal an...

Descripción completa

Detalles Bibliográficos
Autores: Estenaga, Á. (Ángela)|||/items/b25e8df1-8b45-48c6-b23b-a8574237d85e, Rodríguez-Garijo, N. (Nuria)|||/items/4cc7682a-1d4e-413b-ae6c-fc01e5f88a62, Tomás-Velázquez, A. (Alejandra)|||/items/cf4d9572-46c9-42ea-8b01-d2450ddcd205, Antoñanzas-Perez, J. (Javier)|||/items/1a5aa116-61aa-49da-a66e-b56aa0de2f29, Álvarez-Gigli, L. (Laura)|||/items/a8dc006f-2621-4988-97d9-a5e9318f0731, Garcia-Tobar, L. (Laura)|||/items/64b398ed-0d60-4773-9118-e862d5d28ff9, España-Alonso, A. (Agustín)|||/items/a6e3549c-ab30-4d2e-90a5-fd108573bc9f, Salido-Vallejo, R. (Rafael)|||/items/358e939a-9001-4a19-a55d-f8dc95c53c34
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/116722
Acceso en línea:https://hdl.handle.net/10171/116722
Access Level:acceso abierto
Palabra clave:Dermatomyositis
Immune checkpoint inhibitor
Immunotherapy
Complication
Treatment
Descripción
Sumario:To conclude, dermatomyosits can be a serious complication during treatment with immune checkpoint inhibitor, requiring drug discontinuation and systemic corticosteroids in most patients. Clinicians should be aware of this potential complication of immunotherapy and closely monitor musculoskeletal and skin symptoms after drug administration.

Similares en LA Referencia